Search 

Targeting toxic oligomers in misfolded protein diseases is the basis for Crossbeta’s stable oligomer drug discovery platforms which are accessible for partnering in therapeutic areas such as Alzheimer´s, Parkinson’s, Huntington and Diabetes Type 2.

In our Alzheimer program we have recently completed a high throughput screening campaign with 100,000 compounds resulting in the selection of 5 hit classes with >50%  neutralizing effect on oligomer-induced neurotoxicity.

Stable oligomers can also be used as reference in biomarker assays.

DCPrime is a Dutch biotech company which has developed a novel approach to cancer vaccines. The company’s unique platform technology consists of sustainable dendritic progenitor cells (DCOne™) and a proprietary method to expand these and to create functional mature dendritic cells (DC).

These cells, in some indications loaded with cancer antigens for targeted treatment, are used as standardized, off-the-shelf, therapeutic products that can stimulate the patient’s immune system in a specific manner. The platform combines the power of DC-based vaccines with the advantages of allogeneic stimulation of the immune system, and the simple logistics of off-the-shelf products.

DIGNA Biotech is a private biotechnology company headquartered in Pamplona (Spain), with offices in Madrid and Pennsylvania (USA). It was founded in 2004 as a spin-off of the University of Navarra. The firm currently has a pipeline of 9 products at different stages of development in 3 therapeutic areas: Inflammatory/Autoimmune, Cardiovascular and Liver diseases.

 Digna Biotech is seeking private funding to spin out a new biotech company to conduct Phase IIb and Phase III trials of its more advanced candidate, a cytokine inhibitor for the treatment of patients with Systemic Sclerosis and Localized Scleroderma. The product (Disitertide) has already completed Phase I, Phase IIa and open-label extension (OLE) clinical trials under a topical formulation in patients with systemic sclerosis. Orphan drug designation by both FDA and EMA has been granted in the two indications.

eADMET is an expert in the creation of customised computational models for the prediction of ADME/Tox properties of small drug-like molecules. eADMET’s modular approach combines proprietary and selected external algorithms to create customised prediction models (with integrated error estimation) for clients and partners from the pharmaceutical and biotechnology industry.

eADMET’s product portfolio includes:

1. OCHEM - a public accessible reference system and database
2. Validated models for precise prediction of various ADME/Tox parameters
3. User-friendly customized model solutions for specific customer needs
4. Expert consultancy services with respect to model application and interpretations.

New developments include chemogenomic methods and methods for in vitro to in vivo correlations to address toxicity prediction within drug discovery and REACH.

eADMET was founded as a result of GO-Bio project awarded to Dr Tetko with a financial support from High-Tech Gründerfonds (HTGF) and Bayern Kapital. it is a spinout from Helmholtz Centre, Munich.